Login to Your Account

Re-branded Inspyr secures up to $100M as mipsagargin rounds bend

By Marie Powers
News Editor

Friday, March 17, 2017

With multiple phase II studies of lead compound, mipsagargin, under its belt, Inspyr Therapeutics Inc. inked an agreement with private equity firm Milost Global Inc. for up to $100 million to fund the next stage of development.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription